Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics

Radiogenomics is a provocative new area of research based on decades of previous work examining the association between radiological and histological features. Many generalized associations have been established linking anatomical imaging traits with underlying histopathology, including associations between contrast-enhancing tumor and vascular and tumor cell proliferation, hypointensity on pre-contrast T1-weighted images and necrotic tissue, and associations between hyperintensity on T2-weighted images and edema or nonenhancing tumor. Additionally, tumor location, tumor size, composition, and descriptive features tend to show significant associations with molecular and genomic factors, likely related to the cell of origin and growth characteristics. Additionally, physiologic MRI techniques also show interesting correlations with underlying histology and genomic programs, including associations with gene expression signatures and histological subtypes. Future studies extending beyond simple radiology–histology associations are warranted in order to establish radiogenomic analyses as tools for prospectively identifying patient subtypes that may benefit from specific therapies.

[1]  R. Gilbertson,et al.  Stem cells of ependymoma , 2006, British Journal of Cancer.

[2]  Albert Lai,et al.  Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study , 2012, Journal of Neuro-Oncology.

[3]  A. Osborn Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging , 2008 .

[4]  R A Betensky,et al.  Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. , 2001, Cancer research.

[5]  James M Provenzale,et al.  Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. , 2002, Radiology.

[6]  Carlo Pierpaoli,et al.  High Temporal Resolution Diffusion MRI of Global Cerebral Ischemia and Reperfusion , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  T Tolxdorff,et al.  In vivo NMR T2 relaxation of experimental brain tumors in the cat: a multiparameter tissue characterization. , 1992, Magnetic resonance imaging.

[8]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[9]  R. Turner,et al.  Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Ferenc A. Jolesz,et al.  Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme , 2011, PloS one.

[11]  R R Edelman,et al.  Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. , 1990, Radiology.

[12]  S. Schoenberg,et al.  Brain Tumor Enhancement in MR Imaging at 3 Tesla: Comparison of SNR and CNR Gain Using TSE and GRE Techniques , 2007, Investigative radiology.

[13]  T. Cloughesy,et al.  Probabilistic Radiographic Atlas of Glioblastoma Phenotypes , 2013, American Journal of Neuroradiology.

[14]  J. Smirniotopoulos,et al.  Glioblastoma multiforme: radiologic-pathologic correlation. , 1996, Radiographics : a review publication of the Radiological Society of North America, Inc.

[15]  G. Stewart,et al.  Researches on the Circulation Time and on the Influences which affect it , 1897, The Journal of physiology.

[16]  D. Ayer,et al.  Coordination of glucose and glutamine utilization by an expanded Myc network , 2010, Transcription.

[17]  Takashi Aoi,et al.  Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts , 2008, Nature Biotechnology.

[18]  M. Kuo,et al.  Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. , 2007, Journal of vascular and interventional radiology : JVIR.

[19]  A. Giaccia,et al.  The hypoxic tumor microenvironment and gene expression. , 2004, Seminars in radiation oncology.

[20]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[21]  R. Bourgon,et al.  Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]). , 2014 .

[22]  Glyn Johnson,et al.  Dynamic, contrast‐enhanced perfusion MRI in mouse gliomas: Correlation with histopathology , 2003, Magnetic resonance in medicine.

[23]  L. Bozzao,et al.  Radiological assessment of necrosis in glioblastoma: variability and prognostic value , 1998, Neuroradiology.

[24]  D. Nelson,et al.  Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.

[25]  Matthew S. Brown,et al.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.

[26]  S. Atlas,et al.  Magnetic resonance image–guided proteomics of human glioblastoma multiforme , 2003, Journal of magnetic resonance imaging : JMRI.

[27]  William D. Dunn,et al.  MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. , 2013, Radiology.

[28]  P. Kelly,et al.  Glioma vascularity correlates with reduced patient survival and increased malignancy. , 2009, Surgical neurology.

[29]  J. Folkman Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[30]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[31]  K. Aldape,et al.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.

[32]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[33]  A. Rutman,et al.  Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. , 2009, European journal of radiology.

[34]  Mark S. Cohen,et al.  Contrast agents and cerebral hemodynamics , 1991, Magnetic resonance in medicine.

[35]  Paul S Mischel,et al.  MR imaging correlates of survival in patients with high-grade gliomas. , 2005, AJNR. American journal of neuroradiology.

[36]  J. M. Taylor,et al.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.

[37]  Pascal O. Zinn,et al.  A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature , 2012, PloS one.

[38]  B R Rosen,et al.  NMR imaging of changes in vascular morphology due to tumor angiogenesis , 1998, Magnetic resonance in medicine.

[39]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[40]  Naoki Kagawa,et al.  Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors , 2008, NeuroImage.

[41]  M. Scott,et al.  The developmental biology of brain tumors. , 2001, Annual review of neuroscience.

[42]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[43]  Mitchel S Berger,et al.  Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. , 2012, Neuro-oncology.

[44]  P. Lai,et al.  Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI. , 2002, Clinical imaging.

[45]  Isabel Wanke,et al.  Neuroimaging of infections , 2005 .

[46]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[47]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[48]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[49]  B. Rosen,et al.  Perfusion imaging with NMR contrast agents , 1990, Magnetic resonance in medicine.

[50]  W. Curry,et al.  LIMITATIONS OF DIFFUSION‐WEIGHTED IMAGING IN THE DIAGNOSIS OF POSTOPERATIVE INFECTIONS , 2008, Neurosurgery.

[51]  B A Kall,et al.  Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. , 1987, Journal of neurosurgery.

[52]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  B. Rosen,et al.  Functional mapping of the human visual cortex by magnetic resonance imaging. , 1991, Science.

[54]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.

[55]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[56]  B. Rosen,et al.  Dynamic imaging with lanthanide chelates in normal brain: Contrast due to magnetic susceptibility effects , 1988, Magnetic resonance in medicine.

[57]  P. LaViolette,et al.  Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity , 2010, Journal of magnetic resonance imaging : JMRI.

[58]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[59]  P. Basser,et al.  Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. , 1996, Journal of magnetic resonance. Series B.

[60]  Mitchel S Berger,et al.  Neural stem cells and the origin of gliomas. , 2005, The New England journal of medicine.

[61]  Zhaoshi Jiang,et al.  Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Olav Haraldseth,et al.  Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging , 2000, Magnetic resonance in medicine.

[63]  Scott VandenBerg,et al.  Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. , 2007, Neuro-oncology.

[64]  Max Wintermark,et al.  Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project , 2014, BMC Medical Genomics.

[65]  Raymond Sawaya,et al.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme , 2004, Journal of Neuro-Oncology.

[66]  David Gutman,et al.  Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. , 2013, Radiology.

[67]  H. B. Verheul,et al.  Comparison of diffusion‐weighted MRI with changes in cell volume in a rat model of brain injury , 1994, NMR in biomedicine.

[68]  J. Uhm Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[69]  D. Norman,et al.  Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. , 1977, Journal of neurosurgery.

[70]  C. Dang MYC, metabolism, cell growth, and tumorigenesis. , 2013, Cold Spring Harbor perspectives in medicine.

[71]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[72]  Sonja Loges,et al.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.

[73]  D. Zagzag,et al.  Angiogenesis in Gliomas: Biology and Molecular Pathophysiology , 2005, Brain pathology.

[74]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[75]  T Hackländer,et al.  Measurement of cerebral blood volume via the relaxing effect of low-dose gadopentetate dimeglumine during bolus transit. , 1996, AJNR. American journal of neuroradiology.

[76]  K. Zierler,et al.  On the theory of the indicator-dilution method for measurement of blood flow and volume. , 1954, Journal of applied physiology.

[77]  R. Damadian Tumor Detection by Nuclear Magnetic Resonance , 1971, Science.

[78]  P J Basser,et al.  New Histological and Physiological Stains Derived from Diffusion‐Tensor MR Images , 1997, Annals of the New York Academy of Sciences.

[79]  T E Walsh,et al.  Reporting results. , 1969, Archives of otolaryngology.

[80]  Daniel L. Rubin,et al.  The caBIG™ Annotation and Image Markup Project , 2009, Journal of Digital Imaging.

[81]  Sylvia Drabycz,et al.  An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging , 2010, NeuroImage.

[82]  F Di Salle,et al.  Diffusion MRI in patients with transient ischemic attacks. , 1999, Stroke.

[83]  Nancy J Fischbein,et al.  Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. , 2005, AJNR. American journal of neuroradiology.

[84]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[85]  T. Hirai,et al.  Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. , 2006, AJNR. American journal of neuroradiology.

[86]  Robert J. Harris,et al.  Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas , 2012, NeuroImage.

[87]  T. Cloughesy,et al.  Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma , 2012, American Journal of Neuroradiology.

[88]  Howard Colman,et al.  MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. , 2010, Neuro-oncology.

[89]  A. Berns,et al.  Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. , 2000, Genes & development.

[90]  Soonmee Cha,et al.  Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema , 2005, Journal of magnetic resonance imaging : JMRI.

[91]  Franck Couillaud,et al.  MMP‐7 (matrilysin) expression in human brain tumors , 2007, Molecular carcinogenesis.

[92]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[93]  M S Brown,et al.  Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma , 2011, American Journal of Neuroradiology.

[94]  Benjamin M Ellingson,et al.  Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. , 2013, Neuro-oncology.

[95]  Mark R. Gilbert,et al.  Erratum: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma (Neuro-Oncology (2010) 12:2 (116-121)) , 2010 .

[96]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[97]  S. Nelson,et al.  Differential Gene Expression in Glioblastoma Defined by ADC Histogram Analysis: Relationship to Extracellular Matrix Molecules and Survival , 2012, American Journal of Neuroradiology.

[98]  Paul S Mischel,et al.  Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. , 2008, Radiology.

[99]  M T Nieminen,et al.  Potential of diffusion imaging in brain tumors: a review , 2006, Acta radiologica.

[100]  A P Pathak,et al.  MR‐derived cerebral blood volume maps: Issues regarding histological validation and assessment of tumor angiogenesis , 2001, Magnetic resonance in medicine.

[101]  A. Pathak,et al.  Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. , 2003, Neuro-oncology.

[102]  Joel H. Saltz,et al.  The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas , 2010, PloS one.

[103]  D. Rubin,et al.  The Annotation and Image Mark-up project. , 2009, Radiology.